Inhibition of mTOR by rapamycin enhances killing of CML cells by imatinib mesylate and overcomes certain forms of imatinib resistance.

被引：0
|
作者：
Halbur, L [1 ]
Ly, C [1 ]
Ong, ST [1 ]
机构：
[1] Univ Calif Irvine, Dept Med, Dept Hematol Oncol, Irvine, CA USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
242
引用
收藏
页码：72A / 72A
页数：1
相关论文
共 35 条
  • [21] RESISTANCE OF AGGRESSIVE MINOR CML BLAST SUBSET TOWARD BOTH IMATINIB AND NK-CELLS KILLING CAN BE REVERSED BY PGP- MODULATORS
    Galski, H.
    Berlinsky, S.
    Simanovsky, M.
    Oved-Gelber, T.
    Nagler, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 475 - 476
  • [22] Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells
    Minami, Yosuke
    Minami, Miho
    Kuwatsuka, Yachiyo
    Tanizaki, Ryohei
    Nomura, Yuka
    Abe, Akihiro
    Kiyoi, Hitoshi
    Naoe, Tomoki
    BLOOD, 2009, 114 (22) : 1269 - 1269
  • [23] Pgp-mediated resistance toward both imatinib and NK-cells killing of aggressive minor CML blast subset can be reversed by Pgp modulators
    Galski, H.
    Berlinsky, S.
    Simanovsky, M.
    Oved-Gelber, T.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S363 - S364
  • [24] The dual-specific Src and Abl kinase inhibitor (SAKI) CGP76030 overcomes imatinib mesylate resistance in murine bone marrow cells transformed by Bcr-Abl.
    Simon, N
    Susanne, C
    Hallek, MJ
    BLOOD, 2003, 102 (11) : 860A - 860A
  • [25] Leukemic stem cells from CML patients have uniquely elevated BCR-ABL activity explaining their selective resistance to imatinib mesylate but also contain subpopulations with kinase mutations
    Jiang, X
    Delaney, A
    Eaves, A
    Eaves, C
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 50 - 50
  • [26] Modulation of lipid rafts (LR), p-glycoprotein (P-gp) and proinflammatory cytokines (PIC) with HMG-Co A reductase inhibitor simvastatin (SV) in chronic myelogenous leukemia (CML) patients with imatinib mesylate (IM) resistance.
    McPherson, Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Hemin confers resistance to imatinib (Glivec)-induced cell death but enhances nilotinib (AMN107) cytotoxicity in human K-562CML leukemia cells.
    Bonovolias, Ioannis D.
    Manley, Paul W.
    Tsiftsoglou, Asterios S.
    BLOOD, 2006, 108 (11) : 275B - 275B
  • [28] Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph+ Leukemia Cells
    Minami, Yosuke
    Minami, Miho
    Fukushima, Nobuaki
    Kuwatsuka, Yachiyo
    Naoe, Tomoki
    BLOOD, 2011, 118 (21) : 1488 - 1489
  • [29] Imatinib mesylate (ST1571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells
    Suyama, Hisashi
    Igishi, Tadashi
    Ueda, Yasuto
    Shigeoka, Yasushi
    Kodani, Masahiro
    Morita, Masato
    Takeda, Kenichi
    Sumikawa, Takashi
    Nakazaki, Hirofumi
    Matsunami, Keiji
    Matsumoto, Shingo
    Shimizu, Eiji
    ONCOLOGY REPORTS, 2010, 23 (01) : 217 - 222
  • [30] Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy
    Tsurutani, J
    West, KA
    Sayyah, J
    Gills, JJ
    Dennis, PA
    CANCER RESEARCH, 2005, 65 (18) : 8423 - 8432
1234